Ahngook Pharmaceuticals said Tuesday it has secured the government’s support to develop AG-B1512, a growth hormone deficiency medication.
The Korea Health Industry Development 한국보건산업진흥원 has selected AG-B1512 for its project to support the development of new drugs through nonclinical and clinical trials, the company said.
Ahngook Pharmaceutical 안국약품 will receive 1.05 billion won out of the total 1.76 billion won ($1.41 million) expected for the two-year research and hopes to win the approval for Phase 1 clinical trials in advanced countries by next year.
According to the company, AG-B1512 showed 20 to 40 times longer half-life compared to first-generation growth hormone (IGF-1) in an animal trial.
It also confirmed that levels of human insulin-like growth factor-1 (IGF-1), a surrogate marker that stimulates secretion by growth hormone, are maintained until 20 days after single administration.
The company expects to have similar efficacy as the first-generation growth hormone with just one or two administrations a month.
<© Korea Biomedical Review, All rights reserved.>